Business
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company
About this update from Incannex Healthcare Inc.
[{"type":"text","content":"MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company received written confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement after its common stock maintained a closing bid price of $1.00 per share or greater for eleven consecutive business days, from February 27 through March 13, 2026. As a result, the Company has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now considered closed. “We are pleased to have regained compliance with Nasdaq’s minimum bid price requirement, which reinforces our continued listing on the Nasdaq Capital Market and removes a technical overhang that has weighed on the Company,” said Joel Latham, President and Chief Executive Officer of Incannex Healthcare. “With approximately $75 million in cash, no debt, and a disciplined development strategy, we believe Incannex is exceptionally well positioned to advance our pipeline of differentiated clinical programs. This includes the continued development of IHL-42X for obstructive sleep apnea, which has demonstrated statistically significant Phase 2 results, as well as PSX-001 for the treatment of generalized anxiety disorder, which has also generated positive clinical outcomes. As we progress these programs through upcoming milestones, our focus remains on executing our clinical strategy, further de-risking our assets, and unlocking the long-term value of our pipeline for patients and shareholders.” About Incannex Healthcare Inc. Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms an...